Group 1 - The company plans to repurchase shares with a total amount not less than RMB 30 million and not exceeding RMB 50 million [10][24] - The source of funds for the repurchase will be the company's own funds or a special loan from CITIC Bank Nanjing Branch [10][24] - The repurchased shares will be used for employee stock ownership plans or equity incentives [14][21] Group 2 - The repurchase price will not exceed RMB 96.54 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [23][24] - The repurchase will be conducted through centralized bidding on the Shanghai Stock Exchange [16][21] - The repurchase period is set for six months from the date the board approves the plan [11][17] Group 3 - The company aims to enhance investor confidence and improve shareholder returns through this repurchase [14][31] - The total number of shares to be repurchased is estimated to be between 310,753 shares (0.17% of total shares) and 517,920 shares (0.28% of total shares) based on the maximum repurchase amount [21][22] - The board of directors has confirmed that there are no plans for share reductions by major shareholders in the next three to six months [29][30] Group 4 - The board of directors approved the repurchase proposal on April 21, 2025, with unanimous support [13][31] - The company has established a dedicated securities account for the repurchase of shares [36] - The company will disclose the progress of the repurchase plan in a timely manner [36][8]
南微医学科技股份有限公司 关于召开2024年度暨2025年 第一季度业绩说明会的公告